Purine derivatives and methods of use thereof

Details Purine derivatives and methods of use thereof Purine derivatives and methods of use thereof

2006-11-30

2010-06-08

Crane, Lawrence E (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S027620, C536S027630

Reexamination Certificate

active

07732424

ABSTRACT:
The present invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's core body temperature, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ophthalmic condition, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof. The Purine Derivatives include compounds of the following formula:or a pharmaceutically acceptable salt thereofwhereinA is —CH2OHB and C are —OH:D isA and B are trans with respect to each other:B and C are cis with respect to each other:C and D are cis or trans with respect to each other:R1is —H, -halo, —CN, —N(R2)2, —OR2, —SR2, —NHC(O)R2, —NHC(O)N(R2)2, —NHC(O)OR2, —C(O)OR2, —C(O)R2, —C(O)N(R2)2, —OC(O)N(R2)2, —C(halo)3, or —NO2;each R2is independently —H, —C1-C10alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle, —(CH2)n-(8- to 12-membered bicyclic heterocycle), —(CH2)n—(C3-C8monocyclic cycloalkyl), —(CH2)n—(C3-C8monocyclic cycloalkenyl), —(CH2)n—(C8-C12bicyclic cycloalkyl), or —(CH2)n—(C8-C12bicyclic cycloalkenyl);each n is an integer ranging from 0 to 6;each p is an integer ranging from 1 to 6; andeach q is an integer ranging from 1 to 6.

REFERENCES:
patent: 3819613 (1974-06-01), Kawazoe et al.
patent: 3832341 (1974-08-01), Duschinsky
patent: 4242505 (1980-12-01), Kawahara et al.
patent: 4443836 (1984-04-01), Horiuchi et al.
patent: 4968697 (1990-11-01), Hutchison
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5206222 (1993-04-01), Forman et al.
patent: 5219840 (1993-06-01), Gadient et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5280015 (1994-01-01), Jacobson et al.
patent: 5407793 (1995-04-01), Del Nido et al.
patent: 5443836 (1995-08-01), Downey et al.
patent: 5589467 (1996-12-01), Lau et al.
patent: 5604210 (1997-02-01), Nagaoka et al.
patent: 5789416 (1998-08-01), Lum et al.
patent: 6180615 (2001-01-01), Zablocki et al.
patent: 6214807 (2001-04-01), Zablocki et al.
patent: 6326359 (2001-12-01), Monaghan et al.
patent: 6358536 (2002-03-01), Thomas
patent: 6368573 (2002-04-01), Leung
patent: 6403567 (2002-06-01), Zablocki et al.
patent: 6426337 (2002-07-01), Cox et al.
patent: 6440948 (2002-08-01), Zablocki et al.
patent: 6448236 (2002-09-01), Monaghan et al.
patent: 6525032 (2003-02-01), Mantell et al.
patent: 6528494 (2003-03-01), Cox et al.
patent: 6531457 (2003-03-01), Linden et al.
patent: 6534486 (2003-03-01), Allen et al.
patent: 6544960 (2003-04-01), Eldred et al.
patent: 6605597 (2003-08-01), Zablocki et al.
patent: 6638914 (2003-10-01), Fishman et al.
patent: 6753322 (2004-06-01), Mantell et al.
patent: 6875751 (2005-04-01), Imbach et al.
patent: 6921753 (2005-07-01), Mantell et al.
patent: 7238676 (2007-07-01), Mantell et al.
patent: 7423144 (2008-09-01), Jagtap et al.
patent: 2001/0051612 (2001-12-01), Cristalli
patent: 2002/0082240 (2002-06-01), Linden et al.
patent: 2003/0013675 (2003-01-01), Yeadon et al.
patent: 2003/0055021 (2003-03-01), DeNinno et al.
patent: 2003/0078212 (2003-04-01), Li et al.
patent: 2004/0063658 (2004-04-01), Roberts et al.
patent: 2005/0020532 (2005-01-01), Elzein et al.
patent: 2005/0282768 (2005-12-01), Jagtap et al.
patent: 2006/0034941 (2006-02-01), Dobson
patent: 2006/0128652 (2006-06-01), Jagtap et al.
patent: 2007/0191301 (2007-08-01), Jagtap et al.
patent: 2007/0238694 (2007-10-01), Salzman et al.
patent: 2342479 (1975-03-01), None
patent: 0322242 (1989-06-01), None
patent: 2186470 (1974-01-01), None
patent: WO-94/02497 (1994-02-01), None
patent: WO-95/02604 (1995-01-01), None
patent: WO 95/11681 (1995-05-01), None
patent: WO-96/02553 (1996-02-01), None
patent: WO-97/33590 (1997-09-01), None
patent: WO-97/33879 (1997-09-01), None
patent: WO-98/08855 (1998-03-01), None
patent: WO-98/50047 (1998-11-01), None
patent: WO-99/20284 (1999-04-01), None
patent: WO-01/19360 (2001-03-01), None
patent: WO-01/40245 (2001-06-01), None
patent: WO-01/45715 (2001-06-01), None
patent: WO-02/055085 (2002-07-01), None
patent: WO-02/083152 (2002-10-01), None
patent: WO-03/029264 (2003-04-01), None
International Search Report and Written Opinion issued for International Patent Application No. PCT/US2006/045845.
Al-Mughales, J. et al., “The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines,”Clin. Exp. Immunol., vol. 106:230-236 (1996).
Baraldi, Pier Giovanni et al., “Synthesis and Biological Activity of a New Series ofN6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, andN6-Carboxamido Derivatives of Adenosine-5′-N-ethyluronamide as A1and A3Adenosine Receptor Agonists,”J. Med. Chem., vol. 41:3174-3185 (1998).
Beukers, Margot W. et al., “N6-Cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a Very Selective Agonist with High Affinity for the Human Adenosine A1Receptor,”J. Med. Chem., vol. 46:1492-1503 (2003).
Beukers, Margot W. et al., “New, Non-Adenosine, High-Potency Agonists for the Human Adenosine A2B Receptor with an Improved Selectivity Profile Compared to the Reference AgonistsN-Ethylcarboxamidoadenosine,”Journal of Medicinal Chemistry, vol. 47(15):3707-3709 (2004).
Bouma, Maarten G. et al., “Differential Regulatory Effects of Adenosine on Cytokine Release by Activated Human Monocytes,”The Journal of Immunology, vol. 153:4159-4168 (1994).
Bradley, Karri K. et al., “Purine Nucleoside-Dependent Inhibition of Cellular Proliferation in 1321N1 Human Astrocytoma Cells,”The Journal of Pharmacology and Experimental Therapeutics, vol. 299(2):748-752 (2001).
Broadley, Kenneth J. et al., “Drugs modulating adenosine receptors as potential therapeutic agents for cadiovascular diseases,”Exp. Opin. Ther. Patents, vol. 10(11):1669-1692 (2000).
Bruns, Robert F., “Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists,”Can. J. Physiol. Pharmacol., vol. 58:673-691 (1980).
Bruns, Robert F. et al., “Characterization of the A2Adenosine Receptor Labeled by [3H]NECA in Rat Striatal Membrans,”Biological Pharmacology, vol. 89:331-346 (1986).
Camaioni, Emidio et al., “Adenosine Receptor Agonists: Synthesis and Biological Evaluation of the Diastereoisomers of 2-(3-Hydroxy-3-phenyl-1-propyn-1-yl)NECA,”Bioorganic&Medicinal Chemistry, vol. 5(12):2267-2275 (1997).
Cristalli, Gloria et al., “2-Alkynyl Derivatives of Adenosine-5′-N-ethyluronamide: Selective A2Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation,”J. Med. Chem., vol. 37:1720-1726 (1994).
Cristalli, Gloria et al., “2-Alkynyl Derivatives of Adenosine and Adenosine-5′-N-ethyluronamide as Selective Agonists at A2Adenosine Receptors,”J. Med. Chem., vol. 35:2363-2368 (1992).
Cristalli, Gloria et al., “2-Aralkynyl and 2-Heteroalkynyl Derivatives of Adenosine-5′-N-ethyluronamide as Selective A2aAdenosine Receptor Agonists,”J. Med. Chem., vol. 38:1462-1472 (1995).
Dalpiaz, Alessandro et al., “Synthesis and Study of 5′-Ester Prodrugs of N6-Cyclopentyladenosine, a Selective A1Receptor Agonist,”Pharmaceutical Research, vol. 18(4):531-536 (2001).
De Lean, Andre et al., “Validation and Statistical Analysis of a Computer Modeling Method for Quantitative Analysis of Radioligand Binding Data for Mixtures of Pharmacological Receptor Subtypes,”Molecular Pharmacology, vol. 21:5-16 (1982).
DeNinno, Michael P. et al., “3′-Aminoadenosine-5′-uronamides: Discovery of the First Highly Selective Agonist at the Human Adenos

Affiliated with

Also associated with

Rating

Purine derivatives and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Purine derivatives and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine derivatives and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4195006